Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$227.81 USD
-11.62 (-4.85%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $227.67 -0.14 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Fundamental Charts
About Earnings Yield (TTM)
The company's trailing twelve month (TTM) Earning Yield is used to determine whether the company is undervalued or overvalued. The Earning yield an indicator of the company's earnings and the price paid for the stock. The calculation is the inverse of the P/E ratio. The most common use of the Earnings ratio is to compare it to other stocks and to compare the yields to the 10 Year T-Bill. If earnings go up, the yield goes up. If earnings go down, so does the yield. For example: If the yield on the S&P 500 is greater than the 10 Year T-Bill, stocks would be considered undervalued.
CRL 227.81 -11.62(-4.85%)
Will CRL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRL
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Here's Why You Should Retain Charles River (CRL) Stock Now
Other News for CRL
Danaher Q1: The Worst Time Has Already Passed
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology